Orum Therapeutics rakes in $84m Series B

Orum Therapeutics, a developer of targeted protein degraders to treat cancer, has raised $84 million in Series B financing.

Orum Therapeutics, a developer of targeted protein degraders to treat cancer, has raised $84 million in Series B financing. The investors included IMM Investment, KDB Investment and Atinum.

Source: Press Release